Operator
Good day, and welcome to the Invivyd REVOLUTION Program and Measles Update Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to turn the call over to Katie Falzone, Senior Vice President of Finance. Please go ahead.
Katie Falzone
Senior Vice President of Finance
Thank you, Michelle. A short while ago, we issued a press release announcing an update on our REVOLUTION program progress and advancement of our novel potential first- and best-in-class measles monoclonal antibody candidate for the treatment and prevention of measles. That press release and the slides that are being used on today’s webcast can be found in the Investors section of the Invivyd website under the Press Release and Events and Presentations section, respectively.
Today’s discussion will be led by Marc Elia, Chairman of Invivyd’s Board of Directors. He is joined by Dr. Robert Allen, Chief Scientific Officer; and Dr. Michael Mina, Chief Medical Officer.
During today’s discussion, we will be making forward-looking statements concerning, among other things, our research and development activities, our regulatory plans, our future prospects and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation Reform Act and are subject to various risks, assumptions and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only as of the date of
